Latest news and press releases about Mirum Pharmaceuticals, Inc. (MIRM): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia.
Price
| Price | $97.37 |
| Market Cap | $5.9B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -565.87 |
| EV / EBITDA | -7.92 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -410.20% |
| Return on Invested Capital | -13.09% |
| Return on Assets | -82.32% |
| Gross Margin | 81.70% |
| Operating Margin | -17.42% |
| Net Margin | -139.18% |
Related companies: ACAD · ADMA · BLTE · DYN · LGND · PRAX · RARE
Explore sector: Healthcare · Biotechnology
More sections of MIRM: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks